In this fifth installment, Laura R. Bobolts, PharmD, BCOP, and Lisa Raff, MSPharm, BCPS, BCOP, discuss payer considerations when considering reimbursement and formulary inclusion of bispecific agents, as well as how payers keep up-to-date on the evolving landscape of multiple myeloma learning opportunities from bispecific therapy REMS programs.
Senior Vice President, Clinical Strategy and Growth
OncoHealth
Pompano Beach, FL
OncoHealth
Pompano Beach, FL
Director, Pharmacy Operations
Florida Cancer Specialists & Research Institute
Tampa, FL
Florida Cancer Specialists & Research Institute
Tampa, FL
Hematologic Oncologist and Senior Partner, Cancer Care Northwest
Director, Inland Northwest Myeloma/Lymphoma & Transplant Program
Clinical Professor, Elson S. Floyd College of Medicine, Washington State University
Clinical Professor of Medicine, University of Washington School of Medicine
Spokane, WA
Director, Inland Northwest Myeloma/Lymphoma & Transplant Program
Clinical Professor, Elson S. Floyd College of Medicine, Washington State University
Clinical Professor of Medicine, University of Washington School of Medicine
Spokane, WA
Vice President, Pharmacy Services
OneOncology
Nashville, TN
OneOncology
Nashville, TN
Director, Pharmacy Clinical Services
New England Cancer Specialists
Scarborough, ME
New England Cancer Specialists
Scarborough, ME
